Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 4Lymphoid 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Iron-Dextran Complex × Dermatologic × Clear all
NCT06508827 2025-07-09

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Indiana University

Phase 2 Withdrawn
Classical hematologyDermatologic

Anemia, Melanoma, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡